Handelsbanken Fonder AB Acquires 900 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Handelsbanken Fonder AB raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 5.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,815 shares of the biotechnology company’s stock after purchasing an additional 900 shares during the quarter. Handelsbanken Fonder AB’s holdings in Sarepta Therapeutics were worth $1,621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of SRPT. Peregrine Capital Management LLC grew its stake in Sarepta Therapeutics by 12.9% in the 3rd quarter. Peregrine Capital Management LLC now owns 45,178 shares of the biotechnology company’s stock valued at $5,476,000 after purchasing an additional 5,166 shares during the period. Harbor Capital Advisors Inc. grew its stake in Sarepta Therapeutics by 6.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 3,244 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 196 shares during the period. DMC Group LLC grew its stake in Sarepta Therapeutics by 2.9% in the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock valued at $400,000 after purchasing an additional 93 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Sarepta Therapeutics by 5.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 95,865 shares of the biotechnology company’s stock valued at $11,621,000 after purchasing an additional 4,763 shares during the period. Finally, TD Asset Management Inc lifted its position in shares of Sarepta Therapeutics by 377.7% during the 3rd quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock valued at $24,805,000 after buying an additional 161,788 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $128.77 on Friday. The business’s 50-day moving average price is $126.11 and its two-hundred day moving average price is $110.38. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $159.89. The stock has a market cap of $12.17 billion, a P/E ratio of -21.04 and a beta of 0.94. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. During the same quarter last year, the firm posted ($1.24) EPS. The company’s revenue was up 53.6% compared to the same quarter last year. As a group, equities analysts predict that Sarepta Therapeutics, Inc. will post 2.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Citigroup upped their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Evercore ISI upped their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Barclays upped their price target on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Wedbush reaffirmed an “outperform” rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, Mizuho upped their price target on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $156.60.

Insider Activity

In other news, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,096 shares of company stock worth $2,739,419. 7.40% of the stock is currently owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.